From the CMS HCPCS Level II file

Codes and descriptors come from HCPC2026_OCT_ANWEB_09232026.xlsx, the CMS quarterly HCPCS file. HCPCS Level II is maintained by CMS and updated quarterly — confirm a code in the current CMS HCPCS files before billing. October 2026 code changes · What is a J-code?

All J-codes

25 codes starting Q0

J-codes Q0000–Q0999, page 1
CodeDescriptorBilling unitDrugs
Q0138Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)1 mg (non-esrd use)Feraheme, Ferumoxytol
Q0139Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (for esrd on dialysis)1 mg (for esrd on dialysis)Feraheme, Ferumoxytol
Q0144Azithromycin dihydrate, oral, capsules/powder, 1 gram1 gram—
Q0155Dronabinol (syndros), 0.1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen0.1 mg—
Q0161Chlorpromazine hydrochloride, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen5 mg—
Q0162Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimenSee descriptorOndansetron, Ondansetron HCl, Ondansetron ODT
Q0163Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen50 mg—
Q0164Prochlorperazine maleate, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen5 mg—
Q0166Granisetron hydrochloride, 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 24 hour dosage regimen1 mgGranisetron HCl
Q0167Dronabinol, 2.5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen2.5 mgDronabinol, Marinol
Q0169Promethazine hydrochloride, 12.5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen12.5 mg—
Q0173Trimethobenzamide hydrochloride, 250 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen250 mg—
Q0175Perphenazine, 4 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen4 mg—
Q0177Hydroxyzine pamoate, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen25 mg—
Q0180Dolasetron mesylate, 100 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 24 hour dosage regimen100 mg—
Q0181Unspecified oral dosage form, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for a iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimenSee descriptor—
Q0224Injection, pemivibart, for the pre-exposure prophylaxis only, for certain adults and adolescents (12 years of age and older weighing at least 40 kg) with no known sars-cov-2 exposure, and who either have moderate-to-severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments, and are unlikely to mount an adequate immune response to covid-19 vaccination, 4500 mg4500 mg—
Q0234Injection, tocilizumab-bavi, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation only, 1 mg1 mg—
Q0235Injection, monoclonal antibody products with an indication for post-exposure prophylaxis or treatment of covid-19, for hospitalized adults and/or pediatric patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, not otherwise classified, 1 mg1 mg—
Q0237Injection, tocilizumab-anoh, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg1 mg—
Q0238Injection, tocilizumab-aazg, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg1 mg—
Q0249Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg1 mg—
Q0511Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day periodSee descriptor—
Q0512Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day periodSee descriptor—
Q0515Injection, sermorelin acetate, 1 microgram1 microgram—

CPT vaccine product codes

Vaccines are reported with a CPT product code rather than a J-code, plus a separate immunization administration code. Descriptions here are Med-Code’s own; CPT descriptors are licensed by the AMA.

CPT vaccine product codes in Med-Code's directory
CodeDescriptorBilling unitDrugs in directoryType
CPT 90651Vaccine product code for GARDASIL 9 (human papillomavirus 9-valent vaccine)1 doseGardasil 9CPT vaccine product
CPT 90677Vaccine product code for PREVNAR 20 (pneumococcal 20-valent conjugate vaccine)1 dosePrevnar 20CPT vaccine product
CPT 90678Vaccine product code for ABRYSVO (respiratory syncytial virus vaccine, bivalent)1 doseAbrysvoCPT vaccine product
CPT 90679Vaccine product code for AREXVY (respiratory syncytial virus vaccine, adjuvanted)1 doseArexvyCPT vaccine product
CPT 90750Vaccine product code for SHINGRIX (zoster vaccine recombinant, adjuvanted)1 doseShingrixCPT vaccine product

By therapeutic category

Find a J-code by drug name

1,087 brand and generic names, each with its code and billing unit. All drugs A–Z.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free Med-Code account to keep looking up NDCs, J-codes and drugs.

Create a free accountLog in